Cardiac Arrest
01-09-2005, 10:05 PM
A National Cancer Institute trial involving the COX-2 inhibitor celecoxib (Celebrex) has been halted after confirming an approximately 2.5- to 3.4-fold increase in fatal and nonfatal cardiac adverse events compared to individuals in the trial taking placebo (sugar pills). Patients in the trial taking 400 mg twice daily had a 3.4 times greater risk of cardiovascular events compared to placebo, whereas those taking 200 mg twice daily, the risk was 2.5 times greater. The investigational trial was examining the ability of celecoxib to prevent adenomas (tumors that grow from glandular tissue).
A similar study comparing celecoxib 400 mg once daily versus placebo has not shown an increased risk.
Other COX-2 inhibitors have been associated with increased cardiovascular events including myocardial infarction (heart attacks), including Vioxx which was removed from the worldwide market this fall (see Recalls and Alerts from September 30, 2004). More recently, the COX-2 inhibitor valdecoxib (Bextra) has strengthened warnings on not using the drug following heart vessel bypass surgery due to increased risk of heart attack and stroke (see Recalls and Alerts from December 9, 2004).
More information is available at FDA MedWatch.
For additional information: http://story.news.yahoo.com/news?tmpl=story&cid=578&u=/nm/20041217/bs_nm/health_pfizer_dc_15
http://www.reuters.com/newsArticle.jhtml?type=businessNews&storyID=7126961
12/17/2004
وقريبا ال Celecoxib حيلحق بأخوه Rofecoxib :o:
A similar study comparing celecoxib 400 mg once daily versus placebo has not shown an increased risk.
Other COX-2 inhibitors have been associated with increased cardiovascular events including myocardial infarction (heart attacks), including Vioxx which was removed from the worldwide market this fall (see Recalls and Alerts from September 30, 2004). More recently, the COX-2 inhibitor valdecoxib (Bextra) has strengthened warnings on not using the drug following heart vessel bypass surgery due to increased risk of heart attack and stroke (see Recalls and Alerts from December 9, 2004).
More information is available at FDA MedWatch.
For additional information: http://story.news.yahoo.com/news?tmpl=story&cid=578&u=/nm/20041217/bs_nm/health_pfizer_dc_15
http://www.reuters.com/newsArticle.jhtml?type=businessNews&storyID=7126961
12/17/2004
وقريبا ال Celecoxib حيلحق بأخوه Rofecoxib :o: